Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Jul 13;348(9020):94-7.
doi: 10.1016/s0140-6736(96)05228-2.

Visualisation and quantification of rates of atrophy in Alzheimer's disease

Affiliations

Visualisation and quantification of rates of atrophy in Alzheimer's disease

N C Fox et al. Lancet. .

Abstract

Background: Definitive diagnosis of Alzheimer's disease requires histological examination of brain tissue. In life, brain atrophy can be visualised by computed tomography or magnetic resonance (MR) imaging, but the atrophy due to the disease is difficult to distinguish from that caused by normal ageing. We have investigated use of accurate positional matching (registration) and digital subtraction of serially acquired MR brain scans to allow determination of rates of global and regional atrophy.

Methods: This technique was applied to eleven patients with clinically diagnosed Alzheimer's disease and eleven age-matched controls. Each individual had two scans approximately 1 year apart; scan intervals were matched between the groups.

Findings: The median rate of atrophy was significantly greater in the Alzheimer's disease group than in the control group (12.3 [range 5.8 to 23.6] vs 0.3 (-1.2 to 1.7) mL per year; p < 0.0001). There was no overlap between the groups. Furthermore, three non-demented individuals at risk of familial Alzheimer's disease had scans 6-14 months apart and showed greater rates of volume loss than the controls; these three individuals have subsequently developed symptoms.

Interpretation: This technique may be useful for the diagnosis of Alzheimer's disease, the assessment of disease progression, and the evaluation of potential treatments.

PubMed Disclaimer

Comment in

  • Neuroimaging and early Alzheimer's disease.
    Smith AD, Jobst KA, Edmonds Z, Hindley NJ, King EM. Smith AD, et al. Lancet. 1996 Sep 21;348(9030):829-30. doi: 10.1016/s0140-6736(05)65254-3. Lancet. 1996. PMID: 8814011 No abstract available.

Publication types